Obalon Therapeutics, Inc. re-affirmed revenue guidance for the full year of fiscal 2018. The company re-affirmed its full-year 2018 revenue guidance of $9.0 million to $9.9 million and its U.S. sales guidance of between $4.6 million and $5.5 million.